Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07033598 · ClinicalTrials.gov registry record · Phase 2
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
A Phase 2 study of Leukemia, Myelomonocytic, Chronic, sponsored by Theradex.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT07033598 is a Phase 2 study of Leukemia, Myelomonocytic, Chronic that is actively recruiting participants, run by Theradex. The registered enrollment target is 66 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07033598, a Phase 2 study of Leukemia, Myelomonocytic, Chronic, is actively recruiting participants, sponsored by Theradex.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are: * Does pacritinib improve disease control compared to hydroxyurea? * What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia. Participants will be randomly assigned to receive either pacritinib twice a day or hydroxyurea for up to 48 weeks. After treatment ends, participants will be followed for up to one year.
Conditions Studied
Interventions
- DRUG Hydroxyurea
- DRUG Pacritinib
Study Locations (4)
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute at Emory - Atlanta
Minnesota
- Mayo Clinic Rochester - Rochester
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07033598
The ClinicalTrials.gov registry entry for NCT07033598 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theradex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myelomonocytic, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Hydroxyurea is the first listed.
NCT07033598 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Georgia, Minnesota.
Frequently Asked Questions
What is clinical trial NCT07033598 about?
NCT07033598 is a clinical study titled "Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia". The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are: * Does pacritinib improve disease control compared to hydroxyurea? * What medical problems do ...
What is the current status of trial NCT07033598?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2026-01-01. Estimated completion is 2028-12.
What conditions does trial NCT07033598 study?
This clinical trial studies the following conditions: Leukemia, Myelomonocytic, Chronic.
What interventions are being tested in trial NCT07033598?
The interventions under investigation include: Hydroxyurea (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT07033598?
This trial is sponsored by Theradex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07033598 being conducted?
This trial has 4 study locations across Florida, Georgia, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myelomonocytic, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
ACTIVE NOT RECRUITING · Phase 2
-
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.